KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Shares Outstanding (Diluted Average) (2016 - 2025)

Inovio Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 14 years, with the latest figure at $52.2 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 98.99% year-over-year to $52.2 million; the TTM value through Sep 2025 reached $52.2 million, up 98.99%, while the annual FY2024 figure was $27.2 million, 22.49% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $52.2 million at Inovio Pharmaceuticals, up from $38.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $249.4 million in Q3 2022 and bottomed at $17.4 million in Q4 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $27.2 million (2024), against an average of $88.0 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) plummeted 91.18% in 2023 before it soared 98.99% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $17.4 million in 2021, then increased by 14.27% to $19.9 million in 2022, then grew by 11.51% to $22.2 million in 2023, then rose by 22.49% to $27.2 million in 2024, then surged by 92.07% to $52.2 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Shares Outstanding (Diluted Average) are $52.2 million (Q3 2025), $38.8 million (Q2 2025), and $38.6 million (Q1 2025).